Saturday, August 15, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,805
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,805 facts checked against source5,200 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 23, 2026

Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique

View original at globenewswire.com
Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique Dans l'étude de phase 3 SHORE, l'amlitelimab en association avec des traitements topiques a atteint tous les critères d'évaluation principaux et seco…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Global regulatory submissions are planned for second half of 2026

    80% confidence

  • Amlitelimab's safety and efficacy profiles have not been evaluated by any regulatory authority; the product is currently in clinical development

    80% confidence

  • Two additional phase 3 studies, AQUA and ESTUARY, are expected to publish results in second half of 2026

    80% confidence

  • These results validate the new mechanism of action of amlitelimab, which blocks OX40 ligand without destroying T cells, and its ability to normalize the immune system over time

    80% confidence

  • The complete data observed to date reinforces confidence in amlitelimab's potential to offer both every-12-week dosing from treatment start and progressive efficacy through week 52

    80% confidence
Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique — Source | Via News | Via News